Blade Air Mobility Sets Timing for Name Change to Strata Critical Medical and Commencement of Trading Under the New Ticker Symbol “SRTA�
Blade Air Mobility (NASDAQ:BLDE) announced its upcoming name change to Strata Critical Medical, Inc., effective August 28, 2025. This rebranding reflects the company's strategic shift to focus on mission critical logistics and medical services for healthcare providers, following the sale of its Passenger business to Joby Aviation (NYSE:JOBY).
Starting August 29, 2025, the company will trade under the new ticker symbol "SRTA" on the Nasdaq Capital Market, with its warrants trading as "SRTAW". The CUSIP numbers will remain unchanged, and no action is required from securityholders.
Blade Air Mobility (NASDAQ:BLDE) ha annunciato che cambierà nome in Strata Critical Medical, Inc., con efficacia dal 28 agosto 2025. Questo rebranding riflette il cambiamento strategico dell'azienda, che ora si concentrerà sulla logistica mission-critical e sui servizi medici per i fornitori di assistenza sanitaria, a seguito della cessione del suo business passeggeri a Joby Aviation (NYSE:JOBY).
A partire dal 29 agosto 2025, la società sarà quotata con il nuovo ticker "SRTA" sul Nasdaq Capital Market, con i warrant che verranno negoziati come "SRTAW". I numeri CUSIP resteranno invariati e non è richiesta alcuna azione da parte degli azionisti.
Blade Air Mobility (NASDAQ:BLDE) anunció que cambiará su nombre a Strata Critical Medical, Inc., con vigencia a partir del 28 de agosto de 2025. Este cambio de marca refleja el giro estratégico de la compañía hacia la logística crítica para misiones y los servicios médicos para proveedores de salud, tras la venta de su negocio de pasajeros a Joby Aviation (NYSE:JOBY).
A partir del 29 de agosto de 2025, la empresa cotizará bajo el nuevo símbolo "SRTA" en el Nasdaq Capital Market, y sus warrants se negociarán como "SRTAW". Los números CUSIP permanecerán sin cambios y no se requiere ninguna acción por parte de los tenedores de valores.
Blade Air Mobility (NASDAQ:BLDE)� 2025� 8� 28일부� 사명� Strata Critical Medical, Inc.� 변경할 예정이라� 발표했습니다. 이번 리브랜딩은 승객 사업� Joby Aviation (NYSE:JOBY)� 매각� � 의료 제공자를 위한 미션 크리티컬 물류 � 의료 서비스에 주력하려� 회사� 전략� 전환� 반영합니�.
2025� 8� 29일부� 회사� 나스� 캐피� 마켓에서 새로� 티커 "SRTA"� 거래되며, 워런트는 "SRTAW"� 거래됩니�. CUSIP 번호� 변경되지 않으� 증권 보유자는 별도� 조치� 취할 필요가 없습니다.
Blade Air Mobility (NASDAQ:BLDE) a annoncé qu'elle changera de nom pour devenir Strata Critical Medical, Inc., à compter du 28 août 2025. Ce rebranding reflète l'orientation stratégique de la société vers la logistique critique et les services médicaux pour les prestataires de soins, suite à la cession de son activité passagers à Joby Aviation (NYSE:JOBY).
À partir du 29 août 2025, la société sera cotée sous le nouveau symbole "SRTA" sur le Nasdaq Capital Market, et ses warrants seront négociés sous "SRTAW". Les numéros CUSIP resteront inchangés et aucun acte n'est requis de la part des détenteurs de titres.
Blade Air Mobility (NASDAQ:BLDE) hat angekündigt, seinen Namen zum 28. August 2025 in Strata Critical Medical, Inc. zu ändern. Dieses Rebranding spiegelt den strategischen Wandel des Unternehmens wider, das sich nach dem Verkauf seines Passagiergeschäfts an Joby Aviation (NYSE:JOBY) auf missionskritische Logistik und medizinische Dienstleistungen für Gesundheitsanbieter konzentrieren will.
Ab dem 29. August 2025 wird das Unternehmen an der Nasdaq Capital Market unter dem neuen Ticker "SRTA" gehandelt, die Warrants werden als "SRTAW" notiert. Die CUSIP-Nummern bleiben unverändert, und es ist keine Handlung seitens der Wertpapierinhaber erforderlich.
- Strategic focus on healthcare logistics and medical services market
- Clean transition with no impact on securityholder rights
- Complete exit from passenger business segment
NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Blade Air Mobility, Inc. (Nasdaq: BLDE, “Blade� or the “Company�), today confirmed that the previously announced change of its legal name to Strata Critical Medical, Inc is expected to occur this week. The change is intended to reflect the Company’s plan to focus on providing mission critical logistics and medical services to hospitals and healthcare providers throughout the country following the closing of the previously announced agreement to sell Blade’s Passenger business to Joby Aviation, Inc. (NYSE: JOBY).
The name change is expected to occur on August 28, 2025. The Company further anticipates that commencing with the opening of trading on the Nasdaq Capital Market on August 29, 2025, its common stock will trade under the symbol “SRTA� and its public warrants will trade under the symbol “SRTAW�. The CUSIP numbers associated with the Company’s common stock and warrants will not be changing. These changes will not affect the rights of the Company’s securityholders and no action from securityholders is required in connection with these changes.
About Blade Air Mobility
Blade Air Mobility provides air transportation and logistics for hospitals across the United States, where it is one of the largest transporters of human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States, Southern Europe and Western Canada. Based in New York City, Blade's asset-light model, coupled with its exclusive passenger terminal infrastructure and proprietary technologies, is designed to facilitate a seamless transition from helicopters and fixed-wing aircraft to Electric Vertical Aircraft (“EVA� or “eVTOL�), enabling lower cost air mobility that is both quiet and emission-free.
For more information, visit .
Beginning on August 29, 2025, the Company’s website will become: .
Forward-Looking Statements
This press release contains “forward-looking statements� within the meaning of the “safe harbor� provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by the use of words such as "will", “anticipate�, “believe�, “could�, “continue�, “expect", “estimate�, “may�, “plan�, “outlook�, “future�, "target", and “project� and other similar expressions and the negatives of those terms. These statements, which involve risks and uncertainties, relate to the sale of the Company’s Passenger business, the impact and anticipated benefits of such transaction (including the receipt of any contingent consideration), the impact of such divestiture on the Company’s financial performance, the timing when such transaction may be completed, if at all, and the Company’s future prospects, business strategies, financial and operating performance, industry environment, and growth opportunities. These statements are based on management’s current expectations and beliefs, as well as a number of assumptions concerning future events. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.
Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements include: the occurrence of any event, change, or circumstance that could give rise to the termination of the agreement between the Company and Joby or a delay in consummating the transactions contemplated thereby; the effect of the announcement of the proposed transaction on the Company’s business relationships, operating results, and business generally; unexpected costs, charges, or expenses resulting from the proposed divestiture; any failure to realize the anticipated efficiencies and benefits of such transaction; fluctuations in the value of any shares of Joby stock that are issued to us in the transaction, our continued incurrence of significant losses; failure of the markets for our offerings to grow as expected, or at all; our ability to effectively market and sell air transportation as a substitute for conventional methods of transportation; reliance on certain customers in our Passenger segment revenue; the inability or unavailability to use or take advantage of the shift, or lack thereof, to EVA technology; our ability to successfully enter new markets and launch new routes and services; any adverse publicity stemming from accidents involving small aircraft, helicopters or charter flights and, in particular, any accidents involving our third-party operators; any change to the ownership of our aircraft and the challenges related thereto; the effects of competition; harm to our reputation and brand; our ability to provide high-quality customer support; our ability to maintain a high daily aircraft usage rate; changes in consumer preferences, discretionary spending and other economic conditions; impact of natural disasters, outbreaks and pandemics, economic, social, weather, geopolitical, growth constraints, and regulatory conditions or other circumstances on metropolitan areas and airports where we have geographic concentration; the effects of climate change, including potential increased impacts of severe weather and regulatory activity; the availability of aircraft fuel; our ability to address system failures, defects, errors, or vulnerabilities in our website, applications, backend systems or other technology systems or those of third-party technology providers; interruptions or security breaches of our information technology systems; our placements within mobile applications; our ability to protect our intellectual property rights; our use of open source software; our ability to expand and maintain our infrastructure network; our ability to access additional funding; the increase of costs and risks associated with international expansion; our ability to identify, complete and successfully integrate future acquisitions; our ability to manage our growth; increases in insurance costs or reductions in insurance coverage; the loss of key members of our management team; our ability to maintain our company culture; our reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations; effects of fluctuating financial results; our reliance on third-party operators; the availability of third-party operators; disruptions to third-party operators; increases in insurance costs or reductions in insurance coverage for our third-party aircraft operators; the possibility that our third-party aircraft operators may illegally, improperly or otherwise inappropriately operate our branded aircraft; our reliance on third-party web service providers; changes in our regulatory environment; risks and impact of any litigation we may be subject to; regulatory obstacles in local governments; the expansion of domestic and foreign privacy and security laws; the expansion of environmental regulations; our ability to remediate any material weaknesses or maintain internal controls over financial reporting; our ability to maintain effective internal controls and disclosure controls; changes in the fair value of our warrants; and other factors beyond our control. Additional factors can be found in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Blade undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.
Contacts
Media Relations
Lee Gold
Investor Relations
Mat Schneider
